 |
Peregrine Pharmaceuticals to Report Third Quarter FY 2010 Financial Results
Mar 5, 2010
|
7.2 KB |
|
| |
TUSTIN, Calif., March 5, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the third quarter of fiscal year 2010 on March 11, 2010 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST on the same ...
|
|
Peregrine Pharmaceuticals to Present at Two Upcoming Investor Conferences
Mar 1, 2010
|
7.5 KB |
|
| |
TUSTIN, Calif., March 1, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the following upcoming investor conferences:
Peregrine will present at the Cowen and Company 30th Annual Health Care Conference on Monday, March 8, 2010 at 3:15 pm EST. The con...
|
|
New Scientific Publication Highlights Long-Term Survival of Brain Cancer Patients Treated With Peregrine Pharmaceuticals' Cotara(R)
Feb 11, 2010
|
11.9 KB |
|
| |
TUSTIN, Calif., Feb 11, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara(R) for the treatment of patients with gliobl...
|
|
Peregrine Pharmaceuticals to Present at the 12th Annual BIO CEO and Investor Conference
Feb 2, 2010
|
7.1 KB |
|
| |
TUSTIN, Calif., Feb 02, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 3:30 pm EST. The conference will be held at the Waldorf-Astoria Hotel in New York City.
A live webc...
|
|
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
Jan 11, 2010
|
9.7 KB |
|
| |
TUSTIN, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) today announced that Marvin R. Garovoy, MD, has joined the company as head of clinical science. Dr. Garovoy has extensive biotechnology industry experience in the design and conduct of clinical trials for innovative new drugs. At Pe...
|
|
Peregrine Pharmaceuticals to Present at the OneMedForum 2010 Finance Conference
Jan 6, 2010
|
7.0 KB |
|
| |
TUSTIN, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the OneMedForum 2010 Finance Conference on January 13, 2010 at 2:00 p.m. PST. The conference will be held at the Sir Francis Drake Hotel in San Francisco.
A live audio webcast ...
|
|
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
Dec 10, 2009
|
26.7 KB |
|
| |
TUSTIN, Calif., Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the second quarter of fiscal year (FY) 2010 ended October 31, 2009. Total revenue for the second quarter of FY 2010 increased 255% to $6,896,000, compared to $1,941,000 for the comparab...
|
|
Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
Dec 3, 2009
|
7.4 KB |
|
| |
TUSTIN, Calif., Dec 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7:00 a.m. EST and will host a conference call and webcast to discuss the results at 11:30 a.m. EST...
|
|
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Dec 2, 2009
|
11.8 KB |
|
| |
TUSTIN, Calif., Dec 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara(R) in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoc...
|
|
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Nov 18, 2009
|
12.5 KB |
|
| |
TUSTIN, Calif., Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that researchers presented positive data on progress in its federally funded preclinical viral hemorrhagic fever (VHF) program, confirming that its phosphatidylserine (PS)-targeting antibodies bind to VHF vir...
|
|
New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Cancer Model
Nov 10, 2009
|
11.5 KB |
|
| |
TUSTIN, Calif., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with rad...
|
|
Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
Nov 4, 2009
|
12.8 KB |
|
| |
...
|
|
Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
Nov 3, 2009
|
9.3 KB |
|
| |
...
|
|
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Oct 21, 2009
|
10.9 KB |
|
| |
TUSTIN, Calif., Oct 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Ph...
|
|
Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
Oct 19, 2009
|
10.3 KB |
|
| |
TUSTIN, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that Dr. Robert Garnick has joined the company as the head of regulatory affairs. Dr. Garnick was formerly the senior vice president of regulatory, quality and compliance at Genentech. During his 24-year c...
|
|
Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes Effect
Oct 19, 2009
|
9.5 KB |
|
| |
TUSTIN, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the previously announced 1-for-5 reverse stock split of the Company's common stock will become effective at 9:30 a.m. EDT today. Peregrine's shares will continue to trade on the NASDAQ Capital Market un...
|
|
Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
Oct 16, 2009
|
10.4 KB |
|
| |
TUSTIN, Calif., Oct 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that a previously approved reverse split of its common stock will take effect at the start of NASDAQ trading on Monday, October 19, 2009 on a 1-for-5 split-adjusted basis. Peregrine's shares will continue to...
|
|
Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
Oct 7, 2009
|
14.4 KB |
|
| |
TUSTIN, Calif., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has established a new Anti-Viral Research Group in its R&D organization. The new group has responsibility for coordinating, expanding and leveraging the company's multiple external collaborations alr...
|
|
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Oct 5, 2009
|
10.9 KB |
|
| |
TUSTIN, Calif., Oct 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the i...
|
|
Avid Bioservices Becomes U.S. West Coast Partner of Boehringer Ingelheim's Global Production Alliance Network for Biologic Contract Manufacturing Services
Sep 21, 2009
|
11.5 KB |
|
| |
TUSTIN, Calif., Sept 21, 2009 /PRNewswire via COMTEX News Network/ -- Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing of biologics and other key services, and Boehringer Ingelheim, a global leader in biopharmaceutical development and manufacturing, today announced that the two companies have entered into a global strategic...
|
|
|
News Releases 
